Clinical trials: Stage IV Melanoma
Melanoma
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
This was a two-arm, double-blinded, randomized, Phase III study comparing dabrafenib and trametinib combination therapy to dabrafenib administered with a placebo (dabrafenib monotherapy).
- Trial name
- NCT01584648
- Testing
- Dabrafenib, Trametinib
- Where
- 121 sites in United States, Argentina and 12 more
- Volunteers
- 423 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Melanoma
Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma
An attractive area of research regards immune manipulations to recover some of the patient's immune response to his/her tumor, a strategy that has the advantages of being both natural and potentially long-lasting.[1] We propose…
- Trial name
- NCT01689974
- Testing
- Ipilimumab, Radiation Therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- NYU Langone Health
Melanoma
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
The study design included an open-label, dose escalation phase followed by a blinded, randomized phase, which combined epacadostat (an oral IDO1 inhibitor) with an approved therapy and compared to approved therapy plus placebo in…
- Trial name
- NCT01604889
- Testing
- Epacadostat, ipilimumab
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Incyte Corporation
Melanoma
A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma
The purpose of this study is to evaluate the safety of combination therapy with vemurafenib and trientine in patients with BRAF mutated metastatic melanoma.
- Trial name
- NCT02068079
- Testing
- Vemurafenib and Trientine
- Where
- United States
- Sponsor
- Duke University
Breast Cancer, Kidney Cancer
Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Breast Cancer, Kidney Cancer, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00006126
- Testing
- busulfan, cyclophosphamide, etoposide
- Sponsor
- Northwestern University
Metastatic Cancer, Melanoma
Vemurafenib and White Blood Cell Therapy for Advanced Melanoma
Background: One possible treatment for advanced melanoma involves collecting white blood cells from the person with cancer and growing them in a laboratory. The cells can then be given back to the donor.
- Trial name
- NCT01585415
- Testing
- Vemurafenib, Young TIL, Cyclophosphamide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin), Sarcoma
Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Infusing chemotherapy to the tumor area only may kill more tumor cells and cause less damage to healthy…
- Trial name
- NCT00004250
- Testing
- dactinomycin, isolated limb perfusion, melphalan
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
BRAF V600 Mutation, Unresectable Melanoma
Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma
Encorafenib in combination with binimetinib have been approved in USA, Europe, Australia, Japan and Switzerland for the treatment of adult patients with unresectable or metastatic melanoma with BRAF V600 mutation.
- Conditions
- BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma, Hepatic Impairment
- Trial name
- NCT04759846
- Testing
- Encorafenib + Binimetinib
- Where
- 7 sites in Czechia, Italy and 1 more
- Sponsor
- Pierre Fabre Medicament
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
This phase I/II trial studies the best dose and effect of pimasertib in combination with bintrafusp alfa in treating patients with cancer that has spread to the brain (brain metastases).
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm, Hormone Receptor Positive Breast Adenocarcinoma
- Trial name
- NCT04789668
- Testing
- Bintrafusp Alfa, Pimasertib, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Melanoma
Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma
The purpose of this first-in-man study is to evaluate the safety of 188Re-PTI-6D2 in patients with metastatic melanoma. All patients will receive a tracer dose of 188Re-PTI-6D2 in order to provide information on how the…
- Trial name
- NCT00399113
- Testing
- 188Re-PTI-6D2
- Where
- 2 sites in Israel
- Volunteers
- 12 people
- Sponsor
- Pain Therapeutics
Metastatic Melanoma
Isolated Limb Perfusion of Melphalan for Melanoma and Sarcoma Treatment
In-transit metastases occur in approximately 3% of melanoma patients, can be very symptomatic and the survival in this group may be prolonged. In-transit melanoma metastases are often confined to a limb.
- Trial name
- ILI (NCT01920516)
- Testing
- Melphalan
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- International Group of Endovascular Oncology
Unresectable Stage III or Stage IV Melanoma
A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma
This study will evaluate the safety, tolerability and pharmacokinetics of CR011-vcMMAE in patients who have unresectable stage III or stage IV melanoma and have failed no more than 1 line of prior cytotoxic therapy.
- Trial name
- NCT00412828
- Testing
- CR011-vcMMAE
- Where
- 4 sites in United States
- Volunteers
- 117 people
- Sponsor
- CuraGen Corporation
Melanoma (Skin), Metastatic Cancer
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
RATIONALE: Inhaling sargramostim may interfere with the growth of tumor cells and may be an effective treatment for melanoma that has spread to the lung.
- Trial name
- NCT00017121
- Testing
- sargramostim
- Where
- 87 sites in United States
- Volunteers
- 40 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Melanoma
A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
The researchers are doing this study to find out whether the study vaccines, IO102/IO103, given in combination with the standard-of-care drug combination, nivolumab and relatlimab, is a safe and effective treatment for people…
- Trial name
- NCT05912244
- Testing
- IO102/IO103, Nivolumab-Relatlimab
- Where
- 9 sites in United States
- Volunteers
- 43 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma
Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma
This randomized phase II trial is studying vaccine therapy and sargramostim to see how well they work compared to vaccine therapy alone in treating patients who have undergone surgery for stage IIB, stage IIC, stage III, or stage…
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Stage IIB Melanoma
- Trial name
- NCT00089063
- Testing
- tyrosinase peptide, gp100 antigen, MART-1 antigen
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma, Melanoma
Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers
This study evaluates the effectiveness of first-line immunotherapy in patients with metastatic melanoma treated at the Institute of Oncology Ljubljana in Slovenia.
- Trial name
- NCT07407166
- Testing
- Immunotherapy
- Where
- Slovenia
- Volunteers
- 40 people
- Sponsor
- Institute of Oncology Ljubljana
Mucosal Melanoma, Recurrent Melanoma
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
This randomized phase III trial studies carboplatin, paclitaxel, and sorafenib tosylate to see how well they work compared to carboplatin and paclitaxel in treating patients with stage III or stage IV melanoma that cannot be…
- Conditions
- Mucosal Melanoma, Recurrent Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma
- Trial name
- NCT00110019
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 219 sites in United States, Australia
- Volunteers
- 823 people
- Sponsor
- National Cancer Institute (NCI)
Intraocular Melanoma, Melanoma (Skin)
PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma
RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells. Biological therapies, such as thalidomide, may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00238329
- Testing
- PEG-interferon alfa-2b, thalidomide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Stage IV Melanoma, Stage III Melanoma
Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Injecting allovectin-7 into a person's melanoma cells may make the body build an immune response that will kill tumor cells.
- Conditions
- Stage IV Melanoma, Stage III Melanoma, Recurrent Melanoma
- Trial name
- NCT00003646
- Testing
- allovectin-7
- Where
- 3 sites in United States
- Volunteers
- 78 people
- Sponsor
- Vical
Metastatic Melanoma, Melanoma
Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib
The purpose of this study is to see if the combination of Vemurafenib with Decitabine plus Cobimetinib improves the low therapy response rate in subjects with malignant melanoma.
- Conditions
- Metastatic Melanoma, Melanoma, BRAF-mutated Metastatic Melanoma, V600EBRAF-mutated Metastatic Melanoma
- Trial name
- ML28604 (NCT01876641)
- Testing
- Vemurafenib + Cobimetinib, Decitabine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mohammed M Milhem
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.